NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
Clinical Trials
434 trialsNCT07479264 2026-03-18
A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT07476651 2026-03-17
LASER
Seoul National University Hospital
Phase NA Not yet recruiting
NCT07478523 2026-03-17
FAPDIG
University Hospital, Bordeaux
Phase 2 Not yet recruiting
NCT06474091 2026-03-16
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
Mayo Clinic
Enrolling by invitation
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05285358 2026-03-13
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT06381648 2026-03-13
LyMIC
City of Hope Medical Center
Completed
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting
NCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT07454486 2026-03-06
TRACE-BTC
Aarhus University Hospital
Not yet recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07282912 2026-03-04
OLIGOMETS
Yale University
Phase 2 Recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT05497531 2026-02-24
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
Phase NA Recruiting
NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT07260175 2026-02-23
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03445585 2026-02-17
Biobank for Cholestatic Liver Diseases.
Mayo Clinic
Recruiting
NCT04753996 2026-02-17
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Mayo Clinic
Recruiting
NCT07401485 2026-02-10
MAAGIE
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT07223307 2026-02-09
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
Phase 2 Recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05489250 2026-02-05
PLATON
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Terminated
NCT07201519 2026-02-04
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
University of Kentucky
Phase 2 Recruiting
NCT06313203 2026-02-02
TOMCAT
Oslo University Hospital
Phase 2 Recruiting
NCT06290856 2026-01-29
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
Oslo University Hospital
Terminated
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT05993429 2026-01-26
Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma
Qilu Hospital of Shandong University
Completed
NCT05210322 2026-01-23
Percutaneous Cholangiopancreatoscopy Registry
Johns Hopkins University
Active not recruiting
NCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07359586 2026-01-22
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
Zhejiang University
Recruiting
NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06302621 2026-01-15
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1 Recruiting
NCT07344116 2026-01-15
Hepatobiliary and Pancreatic Tumor Biobank
Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting
NCT07235007 2026-01-13
BRAVE
Aichi Medical University
Phase NA Recruiting
NCT07337850 2026-01-13
FAPi-2
Tata Memorial Centre
Recruiting
NCT02917759 2026-01-09
Liver and Biliary Tumor Tissue Registry
Mayo Clinic
Terminated
NCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
NCT05404503 2026-01-06
QuiCo
MarÃa Teresa Moreno Asencio
Enrolling by invitation
NCT07319767 2026-01-06
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Shanghai Zhongshan Hospital
Completed
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT07304388 2025-12-30
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Sun Yat-sen University
Phase 2 Completed
NCT06420349 2025-12-22
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Terminated
NCT04400357 2025-12-18
PORTAL
Ruijin Hospital
Phase NA Completed
NCT07291063 2025-12-18
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Shanghai Zhongshan Hospital
Recruiting
NCT07291947 2025-12-18
PULSAR Combined With Immunotherapy and Chemotherapy
West China Hospital
Phase 1/2 Recruiting